American Regent is dedicated to ensuring the safe use of our products. Below you will find product-specific safety notifications. If you have additional questions, please contact our Drug Information Support Group.
Phone: 888-354-4855 (9am–5pm Eastern Time, Monday – Friday)
Phone: 877-845-6371 (Available outside of normal business hours)
In an effort to reduce medication errors and ensure patient safety, American Regent, Inc. is notifying industry of recent changes to the presentation of our Calcium Chloride Injection, USP vials. Please note that there is a marketed unapproved Calcium Chloride Injection, USP 10% as a drug-shortage product. In addition, the FDA has approved 10% Calcium Chloride Injection, USP. The presentations have different indications, NDCs and cap colors on the vials.
Dear Healthcare Professional, American Regent, Inc., would like to reinforce that the appropriate preparation of ProvayBlue® (methylene blue) injection, 0.5%, USP is with a solution of 50 mL 5% Dextrose in Water. There are reports of potential medication errors associated with the improper preparation of this product using saline (0.9% sodium chloride solution), which led to precipitation of the drug, since chloride reduces the solubility of methylene blue. ProvayBlue® is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
IMPORTANT DRUG ADMINISTRATION INFORMATION
READ PRIOR TO USE OF THIS PRODUCT
All lots of Caffeine and Sodium Benzoate Injection, USP, 250 mg/mL, 2 mL Single Dose Vials, manufactured by Luitpold Pharmaceuticals, Inc. (distributed by American Regent, Inc.) in commercial distribution may exhibit evidence of visible or sub-visible particles. Internal procedures are in place to detect visible particles that may be present in Caffeine and Sodium Benzoate Injection, USP, prior to release. Each lot is 100% inspected by automated inspection machinery that is designed to detect visible particles. In addition to automated inspection, samples of filled product are visually examined by Quality Assurance as part of normal lot release procedures. All lots that have been released for distribution have been inspected in this manner, and have met all release specifications for particulates. However, there is a potential for the transient appearance of particles that represent trace amounts of the product’s active ingredient. As a precautionary measure, a filter must be used for the withdrawal and administration of all lots of Caffeine and Sodium Benzoate Injection, USP.